TMVR has emerged as a therapeutic option for high-risk patients with severe mitral regurgitation (MR). Transcatheter heart valve (THV) thrombosis remains a clinical concern. A 81-year-old male with history of… Click to show full abstract
TMVR has emerged as a therapeutic option for high-risk patients with severe mitral regurgitation (MR). Transcatheter heart valve (THV) thrombosis remains a clinical concern. A 81-year-old male with history of CAD, severe MR s/p TMVR (Intrepid) one-year ago presented with worsening shortness of
               
Click one of the above tabs to view related content.